Regenxbio Inc (RGNX) CFO Sells $445,275.00 in Stock
Regenxbio Inc (NASDAQ:RGNX) CFO Vittal Vasista sold 7,500 shares of Regenxbio stock in a transaction on Monday, October 15th. The shares were sold at an average price of $59.37, for a total value of $445,275.00. Following the transaction, the chief financial officer now owns 142,283 shares in the company, valued at approximately $8,447,341.71. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Vittal Vasista also recently made the following trade(s):
- On Monday, September 17th, Vittal Vasista sold 7,500 shares of Regenxbio stock. The shares were sold at an average price of $74.86, for a total value of $561,450.00.
- On Wednesday, August 15th, Vittal Vasista sold 7,500 shares of Regenxbio stock. The shares were sold at an average price of $65.43, for a total value of $490,725.00.
Shares of NASDAQ RGNX opened at $58.37 on Friday. Regenxbio Inc has a one year low of $23.25 and a one year high of $85.10. The stock has a market capitalization of $2.00 billion, a price-to-earnings ratio of -23.82, a PEG ratio of 12.40 and a beta of -1.19.
A number of hedge funds and other institutional investors have recently modified their holdings of RGNX. Meadow Creek Investment Management LLC purchased a new position in Regenxbio in the second quarter valued at about $141,000. Meeder Asset Management Inc. grew its stake in Regenxbio by 1,212.0% in the second quarter. Meeder Asset Management Inc. now owns 2,178 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 2,012 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in Regenxbio in the second quarter valued at about $157,000. Glen Harbor Capital Management LLC purchased a new position in Regenxbio in the second quarter valued at about $171,000. Finally, SG Americas Securities LLC purchased a new position in Regenxbio in the second quarter valued at about $179,000. Hedge funds and other institutional investors own 80.81% of the company’s stock.
RGNX has been the topic of a number of research analyst reports. TheStreet upgraded Regenxbio from a “d+” rating to a “c” rating in a report on Monday, September 17th. Bank of America downgraded Regenxbio from a “buy” rating to a “neutral” rating and lifted their price target for the company from $64.00 to $80.00 in a report on Monday, July 23rd. Barclays lifted their price target on Regenxbio from $48.00 to $83.00 and gave the company an “overweight” rating in a report on Monday, August 13th. Raymond James lifted their price target on Regenxbio from $76.00 to $96.00 and gave the company an “outperform” rating in a report on Friday, September 7th. Finally, Chardan Capital boosted their target price on Regenxbio from $90.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, July 16th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. Regenxbio currently has a consensus rating of “Hold” and a consensus price target of $77.64.
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
See Also: Discover Your Risk Tolerance
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.